Venture Capitalist Jeffrey Friedland explores the opportunities in the Spark-Up Nation
Jeffrey Friedland is a thought leader on emerging and frontier markets, his VC fund Friedland Global Capital being one of the first to open offices in China in 2003. Based in Colorado, he is the founder and CEO of Intiva Inc, an investment company that builds and operates revenue-generating businesses in the global cannabis industry, founder of ag-tech-based Israel Plant Sciences among other executive roles. Jeffrey correctly predicted $100M investment over the past 12 months into Israel’s cannabis research and recognizes the country’s head start in the sector. Medical cannabis is an integral part of Israel’s healthcare system, with every major university and hospital participating in investigations.
“Israel has more PhD’s per capita than anywhere on the planet. The government has given full support to cannabis as it recognizes the investment potential of this new tech sector, converging and capitalizing on its already successful pharma and agricultural industries,” says Jeffrey.
Despite parts of the world opening up to medical cannabis, Israel’s 50 plus years of scientific research into the plant, their collaborative ecosystem, and their in-depth experience in the growing and extraction of the plant place the country with a clear competitive advantage. Until cannabis is re-scheduled in the US, the ability to conduct research there is virtually impossible and although Canada has a very defined, federally legal medical cannabis program, they have no science to support it.
Jeffrey adds, “I expect to see lots of Canadian investors and licensed producers at this year’s CannaTech, facilitating a big movement of Canadian companies creating strategic ventures and partnerships with Israeli pharma development. The industry is shifting away from the ‘take two tokes and call me in the morning’ attitude.”
Other investors participating in this year’s event, powered by iCan: israel-cannabis, include Bruce Linton, CEO of Canopy Growth; Canada’s first ‘cannabis unicorn’ with $1 billion valuation, Ayelet Torem, named one of the ‘100 most influential people in Israeli Hi-Tech’, and Asher Troppe, CEO of Tress Capital.
Full event details at www.canna-tech.co